Page last updated: 2024-10-30

losartan and Ache

losartan has been researched along with Ache in 13 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty."6.82Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022)
"Treatment with losartan was initiated at a daily dose of 0."5.40Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014)
"Both the angiotensin converting enzyme inhibitor enalapril and the AT1 receptor blocking agent losartan acted similarly on pain threshold and tolerance, pain sensitivity being increased during the two anti-hypertensive treatments."5.10Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade. ( Diolisi, A; Garganico, D; Gaudio, G; Grandi, AM; Guasti, L; Simoni, C; Venco, A; Zanotta, D, 2002)
" Losartan (Los) is known to reduce pain; however, its function in IBS is unclear."4.31Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells. ( Chen, Y; Dai, F; Li, J; Li, L; Liu, X; Mei, L; Meng, R; Quan, X; Shi, H; Sun, Y; Wang, J; Wang, L; Wang, T; Zhang, Y, 2023)
" Delayed exercise after complex orthopaedic trauma results in decreased muscle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilities, recapitulates the effect of exercise on post-injury recovery and may provide an enhanced recovery option for those who are unable to exercise after injury ABSTRACT: Chronic pain and disability after limb injury are major public health problems."3.96Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration. ( Clark, JD; Forman, TE; Goodman, SB; Paine, P; Pajarinen, J; Quarta, M; Rando, TA; Takemura, Y; Tawfik, VL, 2020)
"Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty."2.82Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022)
"Camurati-Engelmann disease (CED) is a rare autosomal dominant disease."1.91Proband and the Brother. ( B, S; Kotha, JP, 2023)
"Treatment with losartan was initiated at a daily dose of 0."1.40Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's3 (23.08)29.6817
2010's3 (23.08)24.3611
2020's6 (46.15)2.80

Authors

AuthorsStudies
Cui, L1
Li, Q1
Guan, W1
Yu, W1
Li, X1
Xia, W1
Jiang, Y1
Sriwatananukulkit, O2
Desclaux, S2
Tawonsawatruk, T2
Srikuea, R2
Himakhun, W2
Likitnukul, S2
Hemstapat, R2
Sun, Y1
Liu, X1
Wang, L1
Li, L1
Quan, X1
Shi, H1
Wang, T1
Mei, L1
Chen, Y1
Zhang, Y1
Li, J1
Meng, R1
Wang, J1
Dai, F1
B, S1
Kotha, JP1
Tawfik, VL1
Quarta, M1
Paine, P1
Forman, TE1
Pajarinen, J1
Takemura, Y1
Goodman, SB1
Rando, TA1
Clark, JD1
Hadipour-Lakmehsari, S1
Al Mouaswas, S1
Ayyavoo, A1
Derraik, JG1
Cutfield, WS1
Hofman, PL1
Costa, AC1
Romero, TR1
Pacheco, DF1
Perez, AC1
Savernini, A1
Santos, RR1
Duarte, ID1
Nemoto, W1
Ogata, Y1
Nakagawasai, O1
Yaoita, F1
Tanado, T1
Tan-No, K1
Pelegrini-da-Silva, A1
Rosa, E1
Guethe, LM1
Juliano, MA1
Prado, WA1
Martins, AR1
Krohn, J1
Bjune, C1
Georgieva, D1
Georgiev, V1
Guasti, L1
Zanotta, D1
Diolisi, A1
Garganico, D1
Simoni, C1
Gaudio, G1
Grandi, AM1
Venco, A1

Reviews

1 review available for losartan and Ache

ArticleYear
Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bone Density

2022

Trials

1 trial available for losartan and Ache

ArticleYear
Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade.
    Journal of hypertension, 2002, Volume: 20, Issue:3

    Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; D

2002

Other Studies

11 other studies available for losartan and Ache

ArticleYear
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells.
    European journal of pharmacology, 2023, May-05, Volume: 946

    Topics: Acetic Acid; Animals; Enema; Irritable Bowel Syndrome; Lipopolysaccharides; Losartan; Neuroglia; Pai

2023
Proband and the Brother.
    The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:1

    Topics: Adult; Camurati-Engelmann Syndrome; Child; Female; Humans; Losartan; Male; Mutation; Pain; Positron

2023
Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration.
    The Journal of physiology, 2020, Volume: 598, Issue:2

    Topics: Angiotensin Receptor Antagonists; Animals; Fibrosis; Fractures, Bone; Hyperalgesia; Losartan; Mice;

2020
Reduction of pain and improved muscle biology with the administration of losartan and delayed exercise in a murine trauma model.
    The Journal of physiology, 2020, Volume: 598, Issue:4

    Topics: Angiotensins; Animals; Losartan; Mice; Orthopedics; Pain; Regeneration

2020
Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Camurati-Engelmann Syndrome; Child; Exercise; Female; Human

2014
Participation of AT1 and Mas receptors in the modulation of inflammatory pain.
    Peptides, 2014, Volume: 61

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Inflammation; Losartan; Male; Mice

2014
The intrathecal administration of losartan, an AT1 receptor antagonist, produces an antinociceptive effect through the inhibiton of p38 MAPK phosphorylation in the mouse formalin test.
    Neuroscience letters, 2015, Jan-12, Volume: 585

    Topics: Analgesics; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Injections, Spinal; Lo

2015
Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter.
    Neuroscience, 2009, Dec-15, Volume: 164, Issue:3

    Topics: Analgesics; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Disease Mode

2009
Uveal effusion and angle-closure glaucoma in primary pulmonary hypertension.
    American journal of ophthalmology, 2003, Volume: 135, Issue:5

    Topics: Aged; Antihypertensive Agents; Conjunctiva; Corneal Edema; Dilatation, Pathologic; Female; Glaucoma,

2003
The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test.
    Pharmacology, biochemistry, and behavior, 1999, Volume: 62, Issue:2

    Topics: Acetic Acid; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit

1999